September 30, 2019

Awny Farajallah, MD, FACP
Vice President, Head US Medical
Bristol-Myers Squibb Company
3401 Princeton Pike
Lawrence Township, NJ 08648
609-302-3927; awny.farajallah@bms.com

NCCN Guidelines® Panel: Esophageal and Esophagogastric Junction Cancers

Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed Opdivo® (nivolumab) clinical data that was presented at the 2019 European Society for Medical Oncology (ESMO) Annual Congress and simultaneous manuscript, which was published in *Lancet Oncology* on September 30, 2019, to the NCCN Esophageal and Esophagogastric Junction Cancers Panel for your consideration.

ATTRACTION-3 (ONO-24 / CheckMate 473) is a phase 3, multicenter, randomized, open-label study, which evaluated the use of nivolumab monotherapy for the second-line treatment of patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) refractory or intolerant to one prior fluoropyrimidine/platinum-based therapy. Patients received either nivolumab monotherapy or investigator’s choice of chemotherapy (docetaxel or paclitaxel) until disease progression or unacceptable toxicity.1,2

The use of nivolumab for the treatment of esophageal squamous cell carcinoma is considered investigational.3

**Rationale:** These data are being submitted in response to a standing request from NCCN for new data.

As part of this submission, the following resources are included for your review:


Thank you for your consideration of this request.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical
Bristol-Myers Squibb Company